- Home
- RLX vs KNSA Comparison
RLX vs KNSA Comparison
Compare RLX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLX
- KNSA
- Stock Information
- Founded
- RLX 2018
- KNSA 2015
- Country
- RLX China
- KNSA United Kingdom
- Employees
- RLX N/A
- KNSA N/A
- Industry
- RLX Medicinal Chemicals and Botanical Products
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- RLX Health Care
- KNSA Health Care
- Exchange
- RLX Nasdaq
- KNSA Nasdaq
- Market Cap
- RLX 2.8B
- KNSA 2.6B
- IPO Year
- RLX 2021
- KNSA 2018
- Fundamental
- Price
- RLX $2.55
- KNSA $40.38
- Analyst Decision
- RLX Hold
- KNSA Strong Buy
- Analyst Count
- RLX 1
- KNSA 7
- Target Price
- RLX $2.25
- KNSA $49.71
- AVG Volume (30 Days)
- RLX 2.0M
- KNSA 523.8K
- Earning Date
- RLX 11-14-2025
- KNSA 10-28-2025
- Dividend Yield
- RLX 0.39%
- KNSA N/A
- EPS Growth
- RLX 19.33
- KNSA N/A
- EPS
- RLX 0.08
- KNSA 0.47
- Revenue
- RLX $459,694,770.00
- KNSA $597,973,000.00
- Revenue This Year
- RLX $59.70
- KNSA $62.63
- Revenue Next Year
- RLX $27.15
- KNSA $29.93
- P/E Ratio
- RLX $30.99
- KNSA $86.37
- Revenue Growth
- RLX 51.58
- KNSA 55.68
- 52 Week Low
- RLX $1.60
- KNSA $17.82
- 52 Week High
- RLX $2.84
- KNSA $42.05
- Technical
- Relative Strength Index (RSI)
- RLX 64.40
- KNSA 61.41
- Support Level
- RLX $2.30
- KNSA $37.61
- Resistance Level
- RLX $2.45
- KNSA $41.27
- Average True Range (ATR)
- RLX 0.08
- KNSA 1.66
- MACD
- RLX 0.01
- KNSA 0.14
- Stochastic Oscillator
- RLX 96.77
- KNSA 84.78
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.